Alpha-synuclein co-pathology in a real-world early Alzheimer's disease cohort - PubMed

4 hours ago

Alpha-synuclein (αSyn) co-pathology is common in Alzheimer's disease (AD), detected via cerebrospinal fluid (CSF) α-synuclein seed amplification assay (αS-SAA).
In a study of 108 individuals with mild cognitive impairment or mild dementia due to suspected AD, 32.3% of biomarker-confirmed AD cases were αS-SAA positive.
αS-SAA positivity was associated with older age and self-reported olfactory impairment but not with other demographic or cognitive features.
Within αS-SAA-positive individuals, rapid eye movement sleep behavior disorder (RBD) presence correlated with faster seeding kinetics.
The study suggests αS-SAA could be significant in early AD, particularly in relation to olfactory dysfunction, but longitudinal follow-up is needed to assess its predictive value for anti-amyloid therapy response.

Hasty Briefsbeta